Method of diagnosing and monitoring malignant breast carcinomas
AssigneeUniversity of Mississippi Medical Center
InventorsCharles F. Streckfus, Lenora G. Bigler, James Tate Thigpen
Life of this patent
Estimating the term…
Abstract
A panel of biomarkers for the diagnosis and treatment of breast cancer was examined in the saliva of a cohort of 1) healthy women, 2) women with benign lesions of the breast and 3) women with diagnosed breast cancer. Recognized tumor markers c-erbB-2 (erb), cancer antigen 15-3 (CA 15-3), and tumor suppresser oncogene protein 53 (p53) were found in the saliva of all three groups of women. The levels of erb and CA 15-3 in the cancer patients evaluated, however, were significantly higher than the salivary levels of healthy controls and benign tumor patients. Conversely, pantropic p53 levels were higher in controls as compared to those women with breast cancer and those with benign tumors.
Claims9
A method of using salivary secretion to diagnose carcinoma of the breast in a human test subject, said method comprising:
- providing a saliva specimen from a human test subject, said specimen including a salivary secretion portion from the saliva glands of the test subject;
- analyzing said salivary secretion portion for the presence of a biomarker for breast carcinoma in said salivary secretion, said presence having an associated salivary concentration, said biomarker selected from the group consisting of cancer antigen 15-3, tumor suppressor oncogene protein 53, oncogene c-erbB-2 and combinations thereof;
- and
- using said salivary secretion concentration to diagnose said human subject.
A post-treatment method of monitoring the inhibition of breast tumor growth, said method comprising:
- providing a human test subject, said subject post-treatment for a malignant tumor, said treatment selected from the group of treatments consisting of surgical operation, chemotherapy and combinations thereof;
- providing a salivary secretion specimen from said subject to develop a post-treatment salivary secretion biomarker panel, said panel having constituents selected from the group consisting of cancer antigen 15-3, tumor suppressor oncogene protein 53, oncogene c-erbB-2 and combinations thereof;
- using said post-treatment and salivary secretion biomarker panel to compare with a pre-treatment reference panel for said subject;
- and
- determining the post-treatment inhibition of breast malignancy by monitoring at least one said salivary secretion biomarker.
Dependencies are inferred from the claim text.